Suppr超能文献

铝在阿尔茨海默病中的作用这一争议能够得到解决吗?针对这一争议有哪些建议的方法以及需要考虑的方法学问题?

Can the controversy of the role of aluminum in Alzheimer's disease be resolved? What are the suggested approaches to this controversy and methodological issues to be considered?

作者信息

Savory J, Exley C, Forbes W F, Huang Y, Joshi J G, Kruck T, McLachlan D R, Wakayama I

机构信息

Department of Pathology, University of Virginia, Charlottesville, Virginia, USA.

出版信息

J Toxicol Environ Health. 1996 Aug 30;48(6):615-35. doi: 10.1080/009841096161104.

Abstract

Aluminum (Al) is unquestionably neurotoxic in both experimental animals and certain human diseases. Minute quantities injected intracerebrally into rabbits will induce severe neurological symptoms and neuropathological features of neurodegeneration. Hyper-aluminemia often develops in patients with renal failure being treated with intermittent hemodialysis on a chronic basis, and in severe cases results in an encephalopathy. Uremic adults and premature infants not on dialysis treatment also can develop encephalopathy due to Al toxicity, as is the case when large amounts of alum are used as a urinary bladder irrigant. There are many other examples of Al-induced neurotoxicity; however, the question as to whether Al presents a health hazard to humans as a contributing factor to Alzheimer's disease is still the subject of debate. Several lines of evidence are presented that have formed the basis of the debate concerning the possible pathogenic role for Al in Alzheimer's disease. Important evidence for an Al-Alzheimer's causal relationship is the observation by laser microprobe mass analysis (LMMS) of the presence of Al in neurofibrillary tangles, although there are conflicting data on the extent of the Al deposition. The relatively poor sensitivity of some of the analytical instruments available for these challenging in situ microanalyses could explain the discrepant results, although LMMS and perhaps secondary ion mass spectrometry (SIMS) appear to be sufficiently sensitive. Harmonization of the techniques is an essential next step. There is new evidence that exposure to Al from drinking water might result in cognitive impairment and an increased incidence of Alzheimer's disease. However, these epidemiological studies have inherent problems that must be scrutinized to determine if an association really does exist. An understanding of a possible enhanced bioavailability of Al in this type of exposure, versus other exposures such as antacid intake or industrial exposure, needs to be considered and explored. There has been one promising clinical trial of the treatment of Alzheimer's disease patients with the Al chelator desferrioxamine (DFO). Further studies are needed, and if confirmation is forthcoming then such data could also support an Al-Alzheimer's disease link as well as suggesting that DFO offers potential as a therapeutic agent. The possibility that iron might be the offending agent needs to be considered since DFO is a very strong iron chelator. The significance of Al-induced neurofibrillary degeneration in experimental animals should be assessed especially in light of new data showing that this model exhibits abnormally phosphorylated tau protein structures in the neuronal perikarya. Thus the key questions that must be answered before it can be asserted that Al possesses causal relationship to Alzheimer's disease, are as follows and are addressed in this present discussion: (1) Are there elevations of the concentration of Al in the brains of Alzheimer's disease patients? (2) Is there a relationship between environmental exposure to Al, particularly in drinking water, and an increased risk of Alzheimer's disease? (3) Is treatment with DFO a potentially useful therapeutic approach and to what extent might beneficial effects of DFO implicate Al in the etiology of Alzheimer's disease? (4) Are there similarities between the experimental animal studies and Alzheimer's disease particularly in the development of abnormal forms of tau seen in neurofibrillary tangles? (5) Does Al promote the deposition of the A beta peptide in Alzheimer's disease? (6) Does hyperaluminemia associated with long-term hemodialysis treatment induce neurofibrillary degeneration? If the answer to each of these six questions is yes, then does this assert that Al possesses a causal relationship to Alzheimer's disease? On the other hand, must all six be met to be able to make this assertion?

摘要

铝(Al)在实验动物和某些人类疾病中无疑具有神经毒性。向兔子脑内注射微量铝会引发严重的神经症状和神经退行性变的神经病理学特征。慢性间歇性血液透析治疗的肾衰竭患者常出现高铝血症,严重时会导致脑病。未接受透析治疗的尿毒症成年人和早产儿也可能因铝中毒而患上脑病,例如大量使用明矾作为膀胱冲洗剂时的情况。还有许多其他铝诱导神经毒性的例子;然而,铝作为阿尔茨海默病的一个致病因素是否对人类健康构成危害仍是一个有争议的话题。有几条证据构成了关于铝在阿尔茨海默病中可能的致病作用的争论基础。铝与阿尔茨海默病存在因果关系的重要证据是通过激光微探针质谱分析(LMMS)观察到神经原纤维缠结中有铝存在,尽管关于铝沉积程度的数据存在矛盾。一些用于这些具有挑战性的原位微分析的分析仪器灵敏度相对较差,这可能解释了结果的差异,尽管LMMS以及可能的二次离子质谱(SIMS)似乎具有足够的灵敏度。技术的统一是接下来必不可少的一步。有新证据表明,饮用含铝水可能导致认知障碍和阿尔茨海默病发病率增加。然而,这些流行病学研究存在一些固有问题,必须仔细审查以确定是否真的存在关联。需要考虑并探究在这种暴露类型中,与其他暴露如摄入抗酸剂或工业暴露相比,铝的生物利用度可能增加的情况。有一项关于用铝螯合剂去铁胺(DFO)治疗阿尔茨海默病患者的临床试验颇具前景。还需要进一步研究,如果能得到证实,那么这些数据也可以支持铝与阿尔茨海默病之间的联系,并表明DFO具有作为治疗药物的潜力。由于DFO是一种非常强的铁螯合剂,需要考虑铁可能是致病因素的可能性。铝诱导的实验动物神经原纤维变性的意义应该得到评估,特别是鉴于新数据表明该模型在神经元胞体中表现出异常磷酸化的tau蛋白结构。因此,在断言铝与阿尔茨海默病存在因果关系之前必须回答的关键问题如下,并在本讨论中进行探讨:(1)阿尔茨海默病患者大脑中的铝浓度是否升高?(2)环境暴露于铝,特别是饮用含铝水,与阿尔茨海默病风险增加之间是否存在关系?(3)用DFO治疗是否是一种潜在有用的治疗方法,以及DFO的有益效果在多大程度上可能意味着铝在阿尔茨海默病病因中起作用?(4)实验动物研究与阿尔茨海默病之间是否存在相似之处,特别是在神经原纤维缠结中看到的异常tau形式的发展方面?(5)铝是否促进阿尔茨海默病中β淀粉样肽的沉积?(6)与长期血液透析治疗相关的高铝血症是否会诱导神经原纤维变性?如果这六个问题的答案都是肯定的,那么这是否断言铝与阿尔茨海默病存在因果关系?另一方面,是否必须满足所有六个条件才能做出这一断言?

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验